The Impact of Metabolism Abnormalities on Cardiovascular Disease with Psychiatric Disorder- A review

Abstract

Background: Insulin resistance, obesity, dyslipidemia, and hypertension are metabolic pathologies that are key risk factors of cardiovascular disease (CVD). The abnormalities are often witnessed in patients who have psychiatric conditions such as schizophrenia, bipolar disorder and major depression. Psychiatric illness is associated with metabolic dysfunction which is manifested by shared biological processes especially neuroendocrine dysregulation, chronic inflammation and oxidative stress, leading to premature cardiovascular morbidity and mortality.

Purpose: To investigate the effects of the metabolic abnormalities on cardiovascular disease in patients with psychiatric disorders to emphasize the underlying biological processes, pharmacologically and behaviourally determined factors, and the diagnostic and preventive interventions in integrated clinical management.

Main Body: The present review is a synthesis of the evidence-based studies on peer-reviewed articles published between 2012 and 2025 and retrieved in databases like PubMed, Scopus, and ScienceDirect. The results indicate that both psychiatric and metabolic dysfunction are based on chronic hypothalamic-pituitary-adrenal (HPA) axis activation, systemic inflammation, and oxidative imbalance. Anxious as they are essential to their therapy, second-generation antipsychotics worsen insulin resistance, lipid imbalance, and endothelial damage. Cardiometabolic risk is further aggravated by behavioral and socioeconomic risk factors such as sedentary lifestyle, unhealthy diet, smoking, and low access to healthcare. There is a 10-20-year life expectancy difference between people with severe mental illness (SMI) in the world, chiefly caused by the avoidance of cardiovascular complications. Multidisciplinary coordination between psychiatrists, cardiologists, and endocrinologists is important in reducing this burden by means of early metabolic screening and lifestyle modification.

Conclusion: Metabolic, psychiatric, and cardiovascular dysfunction convergence constitutes a self-perpetuating pathophysiological cycle that requires combined diagnostic and preventive treatment. Frequent cardiovascular surveillance, sensible psychopharmacology and change of lifestyle can make the psychiatric group significantly decrease cardiovascular deaths and increase overall wellness. Precision strategies based on biomarkers should be considered in future research since they can be used to identify people at high risk and direct them to specific interventions.